Zhifeng Dong

Dr. Zhifeng Dong


Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
9 August 2021 in Bioactive Materials
Verified
Journal Article
Open access
LLLi Liang
Li Liang
YSYi Shen
Yi Shen
ZDZhifeng Dong
Zhifeng Dong
XGXin Gu
Xin Gu
Stem cell-derived exosomes (SC-EXO) was an emerging therapeutic agent in regenerative medicine. Intratunical injection of SC-EXO is considered as a prospective approach for erectile dysfunction (ED) treatment. However, high vascularization of cavernous body makes effective retention a major challenge for SC-EXO intratunical injection. In this study, a Polydopamine nanoparticles (PDNPs) incorporated poly (ethylene glycol)-poly(ε-caprolactone-co-lactide) (PDNPs-PELA) thermosensitive hydrogels were fabricated by a facile in situ polymerization for intratunical administration of adipose stem cell-derived exosomes (EXO). The hydrogels exhibited sol-gel transition at body temperature. Moreover, the in-situ polymerization of PDNPs using poly (ethylene glycol)-poly(ε-caprolactone-co-lactide) (PELA) block copolymer as a template was found to be more stable dispersion in the gel system. After being encapsulated into the hydrogel, EXO shows sustained release behavior within two weeks. In vivo animal experiments revealed that exosomes released from hydrogel lead to the healing of endothelial cells and neurons, increase of the cavity's pressure, thereby restoring the erectile function. In particular, since the PDNPs in thermosensitive gels have excellent photoacoustic performance, the hydrogel can be accurately delivered into the tunica albuginea by the guidance of real-time photoacoustic imaging. These results suggest that the as-prepared PDNPs-PELA has a promising future as an injectable exosome carrier for ED treatment.

7 October 2024 in International Immunopharmacology
Verified
Journal Article
Closed access
PYPeng Yin
Peng Yin
ZSZhaoliang Su
Zhaoliang Su
XSXiaozheng Shu
Xiaozheng Shu
ZDZhifeng Dong
Zhifeng Dong
YTYu Tian
Yu Tian

12 September 2022 in Acta Neurologica Belgica
Verified
Journal Article
Closed access
PDF file
YSYuan Shen
Yuan Shen
ZDZhifeng Dong
Zhifeng Dong
JZJianGuo Zhong
JianGuo Zhong
PPPingLei Pan
PingLei Pan
GXGang Xu
Gang Xu
HSHaiCun Shi
HaiCun Shi

26 July 2025 in International Journal of Obesity
Verified
Journal Article
Closed access
PDF file
YTYu Tian
Yu Tian
PWPingping Wang
Pingping Wang
ZDZhifeng Dong
Zhifeng Dong

26 March 2024 in World Neurosurgery
Verified
Journal Article
Closed access
YSYuan Shen
Yuan Shen
MLMingchao Li
Mingchao Li
SWShuFang Wang
ShuFang Wang
LXLei Xia
Lei Xia
XNXiaoyu Ni
Xiaoyu Ni
ZDZhifeng Dong
Zhifeng Dong

20 May 2025 in Research Square
Verified
Preprint
Open access
PDF file
CZChenglin Zhang
Chenglin Zhang
LCLu Cai
Lu Cai
HSHui Sun
Hui Sun
XLXuemei Li
Xuemei Li
XLXiaoyan Li
Xiaoyan Li
ZDZhifeng Dong
Zhifeng Dong
BACKGROUND—Repeated episodes of atrial fibrillation (AF) can shorten event-free survival time in patients. Patient-reported outcomes (PROs) directly reflect the health status of patients. However, the relationship between PROs and cardiac event-free survival remains unclear. OBJECTIVE—This study aimed to investigate the status of PROs and their correlation with cardiac event-free survival time in patients with AF. METHODS—This study was a prospective study. Patients with non-valvular atrial fibrillation treated in the Department of Cardiology of one three third-class hospital in Yancheng from May 2023 to April 2024 were enrolled. The investigation was performed using general information questionnaire and AF-specific questionnaire 6 (AF6). At baseline, demographic and clinical data of the patients were collected. Major adverse cardiovascular events and one-year event-free survival time after discharge were obtained by telephone follow-ups and review of medical records. RESULTS— Among the 197 patients investigated, the mean age was (74.1 ± 9.0) years old, and 106 (53.8%) were women. The mean AF6 score was (24.29 ± 8.33), with over 50% of patients scoring ≥ 1 point on all six items. A significant correlation was observed between cardiac function grading and PROs (r = 0.360, P < 0.001). Kaplan-Meier plots and log-rank tests demonstrated that patients with poor PROs had significantly worse cardiac event-free survival (P = 0.043). CONCLUSION—The PROs of patients with AF were at a moderate level. Poor PROs were associated with the shorter cardiac event-free survival times. These findings highlight the requirement for intervention studies aimed at improving PROs. Clinical trial number Not applicable.